Comparison between application of platelet rich plasma and mucosal advancement flap in patients with high transsphincteric anal fistulas: a randomized control trial.


Journal

ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634

Informations de publication

Date de publication:
05 2022
Historique:
revised: 27 02 2022
received: 13 11 2021
accepted: 06 03 2022
pubmed: 30 4 2022
medline: 12 5 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

There is still a search for a standard method of therapy for high anal fistulas. The aim of this trial was a comparison between a modified two stage minimally invasive procedure, consisting of loose-seton placement with the subsequent application of platelet rich plasma with mucosal advancement flap for the treatment of high transsphincteric anal fistulas of crypto-glandular origin. The study was designed as a prospective, randomized trial including 96 patients. Curettage of fistulous tracts, and loose-seton placement was performed in those patients with active inflammation, and if the diameter of a fistulous tract exceeded 3 mm. Afterwards, the patients were randomly assigned to either the PRP group or MAF group, consisting of 49 patients, and 47 patients, respectively. There was no significant statistical difference (p = 0.152) between both investigated groups of patients regarding closure of fistulas since it was achieved in 35 (71.43%) patients from group I, compared to 27 (57.45%) patients from group II. The diameter of fistulous tracts below 4 mm exerted a significant impact (p < 0.001) on the healing process after PRP application because fistulas with the narrow tracts were closed in 34 (87.18%) patients, whereas a wider fistula was healed in 1 (10%) patient. The local application of PRP in high, unbranched, and with narrow tracts trans-sphincteric anal fistulas of crypto-glandular origin, following loose-seton drainage is an effective, simple, and a safe method of therapy with a low rate of morbidity.

Sections du résumé

BACKGROUND
There is still a search for a standard method of therapy for high anal fistulas. The aim of this trial was a comparison between a modified two stage minimally invasive procedure, consisting of loose-seton placement with the subsequent application of platelet rich plasma with mucosal advancement flap for the treatment of high transsphincteric anal fistulas of crypto-glandular origin.
METHODS
The study was designed as a prospective, randomized trial including 96 patients. Curettage of fistulous tracts, and loose-seton placement was performed in those patients with active inflammation, and if the diameter of a fistulous tract exceeded 3 mm. Afterwards, the patients were randomly assigned to either the PRP group or MAF group, consisting of 49 patients, and 47 patients, respectively.
RESULTS
There was no significant statistical difference (p = 0.152) between both investigated groups of patients regarding closure of fistulas since it was achieved in 35 (71.43%) patients from group I, compared to 27 (57.45%) patients from group II. The diameter of fistulous tracts below 4 mm exerted a significant impact (p < 0.001) on the healing process after PRP application because fistulas with the narrow tracts were closed in 34 (87.18%) patients, whereas a wider fistula was healed in 1 (10%) patient.
CONCLUSION
The local application of PRP in high, unbranched, and with narrow tracts trans-sphincteric anal fistulas of crypto-glandular origin, following loose-seton drainage is an effective, simple, and a safe method of therapy with a low rate of morbidity.

Identifiants

pubmed: 35486027
doi: 10.1111/ans.17656
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1137-1141

Informations de copyright

© 2022 Royal Australasian College of Surgeons.

Références

Narang SK, Keogh K, Alam NN, Pathak S, Daniels IR, Smart NJ. A systematic review of new treatments for cryptoglandular fistula in ano. Surgeon 2017; 15: 30-9.
van der Hagen SJ, Baeten CG, Soeters PB, van Gemert WG. Long-term outcome following mucosal advancement flap for high perianal fistulas and fistulotomy for low perianal fistulas: recurrent perianal fistulas: failure of treatment or recurrent patient disease? Int. J. Colorectal Dis. 2006; 21: 784-90.
Freymiller EG. Platelet-rich plasma: evidence to support its use. J. Oral Maxillofac. Surg. 2004; 62: 1046-8.
Eitan A, Koliada M, Bickel A. The use of the loose seton technique as a definitive treatment for recurrent and persistent high trans-sphincteric anal fistulas: a long-term outcome. J. Gastrointest. Surg. 2009; 13: 1116-9.
Mitalas LE, van Wijk JJ, Gosselink MP, Doornebosch P, Zimmerman DDE, Schouten WR. Seton drainage prior to transanal advancement flap repair: useful or not? Int. J. Colorectal Dis. 2010; 25: 1499-502.
Podetta M, Scarpa CR, Zufferey G et al. Mucosal advancement flap for recurrent complex anal fistula: a repeatable procedure. Int. J. Colorectal Dis. 2019; 34: 197-200.
Uribe N, Millán M, Minguez M et al. Clinical and manometric results of endorectal advancement flaps for complex anal fistula. Int. J. Colorectal Dis. 2007; 22: 259-64.
Moreno-Serrano A, García-Díaz JJ, Ferrer-Márquez M. Using autologous platelet-rich plasma for the treatment of complex fistulas. Rev. Esp. Enferm. Dig. 2016; 108: 123-8.
Van der Hagen SJ, Baeten CG, Soeters PB, van Gemert WG. Autologous platelet-derived growth factors (platelet-rich plasma) as an adjunct to mucosal advancement flap in high cryptoglandular perianal fistulae: a pilot study. Colorectal Dis. 2011; 13: 215-8.
Streit-Ciećkiewicz D, Futyma K, Miotła P, Grzybowska ME, Rechberger T. Platelet-rich plasma as adjuvant therapy for recurrent vesicovaginal fistula: a prospective case series. J. Clin. Med. 2019; 8: 2122.
Gupta S, Goil P, Thakurani T. Autologous platelet rich plasma as a preparative for resurfacing burn wounds with split thickness skin grafts. World J. Plast. Surg. 2020; 9: 29-32.
de la Portilla F, Jiménez-Salido A, Araujo-Miguez A et al. Autologous platelet-rich plasma in the treatment of perianal fistula in Crohn's disease. J. Gastrointest. Surg. 2020; 24: 2814-282.
Kontovounisios C, Tekkis P, Tan E, Rasheed S, Darzi A, Wexner SD. Adoption and success rates of perineal procedures for fistula-in-ano: a systematic review. Colorectal Dis. 2016; 18: 441-58.
Emile SH, Elfeki H, Thabet W et al. Predictive factors for recurrence of high transsphincteric anal fistula after placement of seton. J. Surg. Res. 2017; 213: 261-8.
Mei Z, Wang Q, Zhang Y et al. Risk factors for recurrence after anal fistula surgery: a meta-analysis. Int. J. Surg. 2019; 69: 153-64.

Auteurs

Jacek Hermann (J)

Department of General, and Endocrine Surgery, and Gastroenterologic Oncology, Poznań University of Medical Sciences, Poznań, Poland.

Jarosław Cwaliński (J)

Department of General, and Endocrine Surgery, and Gastroenterologic Oncology, Poznań University of Medical Sciences, Poznań, Poland.

Tomasz Banasiewicz (T)

Department of General, and Endocrine Surgery, and Gastroenterologic Oncology, Poznań University of Medical Sciences, Poznań, Poland.

Barbara Kołodziejczak (B)

Faculty of Mathematics and Computer Science, Adam Mickiewicz University, Poznań, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH